ChengDa Pharmaceuticals Co. Ltd. (301201) - Total Liabilities
Based on the latest financial reports, ChengDa Pharmaceuticals Co. Ltd. (301201) has total liabilities worth CN¥249.97 Million CNY (≈ $36.58 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ChengDa Pharmaceuticals Co. Ltd. (301201) net asset momentum to track the company's year-over-year net asset growth rate.
ChengDa Pharmaceuticals Co. Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of ChengDa Pharmaceuticals Co. Ltd. to measure how efficiently the company converts operating cash flow to free cash.
ChengDa Pharmaceuticals Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of ChengDa Pharmaceuticals Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
2CRSI S.A.
PA:AL2SI
|
France | €69.81 Million |
|
Advanced Power Electronics Corp
TW:8261
|
Taiwan | NT$776.60 Million |
|
Qualitas Ltd
AU:QAL
|
Australia | AU$88.55 Million |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥442.16 Million |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
China | CN¥865.89 Million |
|
President Bakery Public Company Limited
BK:PB
|
Thailand | ฿1.13 Billion |
|
Reitir fasteignafélag hf
IC:REITIR
|
Iceland | Ikr174.57 Billion |
|
Beijing SPC Environment Protection Tech Co Ltd
SHE:002573
|
China | CN¥16.85 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down ChengDa Pharmaceuticals Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 301201 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ChengDa Pharmaceuticals Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ChengDa Pharmaceuticals Co. Ltd. (2019–2024)
The table below shows the annual total liabilities of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥290.77 Million ≈ $42.55 Million |
+64.83% |
| 2023-12-31 | CN¥176.40 Million ≈ $25.81 Million |
+66.71% |
| 2022-12-31 | CN¥105.81 Million ≈ $15.48 Million |
-30.98% |
| 2021-12-31 | CN¥153.30 Million ≈ $22.43 Million |
+103.59% |
| 2020-12-31 | CN¥75.30 Million ≈ $11.02 Million |
-60.20% |
| 2019-12-31 | CN¥189.21 Million ≈ $27.69 Million |
-- |
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food… Read more